By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ACADIA Pharmaceuticals, Inc. 

3911 Sorrento Valley Boulevard

San Diego  California  92121   U.S.A.
Phone: 858-558-2871 Fax: 858-558-2872


ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.


July 16, 1993


Founder: Mark Brann

CEO: Stephen Davis

CMO (Medical): Randall Owen


Please click here for Acadia Pharma job opportunities.


Please click here for clinical trial information.


All Products

Key Statistics

Ownership: Public

Web Site: Acadia
Employees: 140
Symbol: ACAD

Drug Discovery


Allergan  Discovery of alpha adrenergic drug candidates that may represent a significant breakthrough in the treatment of neuropathic pain.

Allergan  Develop and commercialize selective muscarinic drugs for the treatment of glaucoma.

Allergan  The third collaboration is designed to leverage ACADIA's R&D platform to discover and develop new therapeutics predominantly in the area of pain.

Sunovion  ACADIA has formed a broad CNS collaboration with Sepracor for the discovery and development of new drug candidates against muscarinic receptors.

Company News
Always a Bridesmaid, Never a Bride: Acadia (ACAD) Moves Higher on Takeover Speculation 2/6/2017 6:05:59 AM
Acadia (ACAD) Stock Screams Upward; Primary Endpoint Met in Phase II Study of Pimavanserin for Alzheimer’s 12/20/2016 7:07:39 AM
Acadia (ACAD) Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Major Depressive Disorder 12/1/2016 7:59:07 AM
Acadia (ACAD) Initiates Phase II Trial Of Pimavanserin For Adjunctive Treatment In Patients With Negative Symptoms Of Schizophrenia 11/15/2016 11:08:33 AM
Acadia (ACAD) Reports Third Quarter 2016 Financial Results 11/8/2016 10:44:17 AM
Acadia (ACAD) Initiates Phase III Trial Of Pimavanserin For Adjunctive Treatment In Patients With Schizophrenia 11/3/2016 11:30:59 AM
Acadia (ACAD) To Announce Third Quarter 2016 Financial Results On November 7, 2016 11/1/2016 11:45:18 AM
Acadia (ACAD) Initiates Phase II Study Of Pimavanserin In Alzheimer’s Disease Agitation 10/31/2016 9:13:35 AM
Acadia (ACAD) Receives California Life Sciences Association’s 2016 Pantheon Dina Award For Outstanding Therapeutic Product For NUPLAZID 10/11/2016 10:57:10 AM
Acadia (ACAD) Sponsors National Parkinson Foundation’s Caregiver Summit 9/19/2016 11:59:50 AM